Eli Lilly and Co. (NYSE:LLY) is set to report fourth-quarter earnings on Feb. 4 before the opening bell, with Wall Street forecasting a significant revenue beat driven by its blockbuster weight-loss and diabetes drugs.

While topline expectations are high, surging research costs could challenge the company's ability to hit ambitious profit targets.

Revenue Expectations Vs. Guidance

Analysts project fourth-quarter revenue of $17.90 billion, as per Benzinga, a figure that exceeds the implied ceiling of management's own guidance.

During the third quarter, Lilly raised its full-year 2025 revenue outlook to a range of $63.0 billion to $63.5 billion, implying a fourth-quarter cap of approximately $17.6 billion.

The optimism stems from the continued dominance of Mounjaro and Zepbound. In the previous quarter, CEO David A. Ricks noted, “Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued demand for our incretin portfolio”.

Investors will be watching to see if volume growth can continue to offset pricing pressures, which saw U.S. realized prices decline in the third quarter.

The Cost Of Innovation

Profitability remains a key battleground. The consensus earnings per share (EPS) ...